For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00United Kingdom
+44 (0)20 36 36 94 00France
+33 (0)18 375 62 73We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United Kingdom
+44 (0)20 36 36 94 00United States of America
+1 (0)21 237 601 34Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.